DIRS.INFO The most relevant business & tech news

☆ A part-time trader who gained 127% in 5 months this year shares how he finds stocks and an 'immediate' buy signal for an imminent breakout
▼ + stars: | 2024-07-13 | by ( Laila Maidan | ) www.businessinsider.com time to read: +5 min

Read previewJohn Rodrigues works a full-time 9-to-5 job as an associate manager in operations at PGIM, Prudential's investment management arm. And vice versa, if the index is high, it signals high volatility and fearful investors, indicating that the market may be reaching a low. Here, he can see different metrics for stocks, allowing him to watch for signals he likes to trade on. He also looks at the stock's day's volume; if it rises above 25% of its 50-day volume, it's another likely trade. But perhaps one of the best signals that a breakout is about to really outperform the market is those with very high volume relative to the past two years.

Persons: —, John Rodrigues, doesn't, Bob Brinker, Brinker, Rodrigues, Norman Zadeh, " Rodrigues Organizations: Service, New York Stock Exchange, Business, Companies, Nasdaq, Investors Intelligence, IBD, Micro Locations: PGIM, Chicago

☆ Scientists have discovered a cause of inflammatory bowel disease. They said it's a 'holy grail' discovery that could transform treatments.
▼ + stars: | 2024-06-06 | by ( ) www.businessinsider.com time to read: +4 min

Read previewScientists have reported a major breakthrough in our understanding of inflammatory bowel disorder. The underlying pathway for inflammatory bowel disease had previously been poorly understood, making it difficult to find treatments. They dialed up the ETS2 in macrophages in the lab, and sure enough, inflammation similar to that seen in patients with inflammatory bowel disease. Conditions like inflammatory bowel disease and Crohn's disease affect almost 5% of the population, and there is currently no cure. AdvertisementUnderstanding the potential biological pathways that underlie these diseases could also help researchers fight inflammatory conditions like autoimmune disorders, too.

Persons: —, Francis Crick, Dr James Lee, gastroenterologist, Lee, we're, Christina Stankey Organizations: Service, University College London, Business, Royal Free Hospital, Guardian, Francis, Francis Crick Institute Locations: IBD, Nature

☆ An engineer who trades stocks from his phone shares the stock filter that enabled him to find Nvidia when it was trading below $15 in 2016
▼ + stars: | 2024-05-12 | by ( Laila Maidan | ) www.businessinsider.com time to read: +6 min

IBD recommends a minimum of 25% increase, but he loosened it slightly because it would filter out too many stocks. IBD recommends 80 or higher. IBD recommends 80, but reducing it allows for more stocks to show up for him to review. IBD recommends 95 or higher, but he loosened it to see more stocks. IBD recommends 15% to 17%.

Persons: Adam Graham, Nicolas Darvas, Graham, William O'Neil, IBD Organizations: Service, Business, Investor's Business, Nvidia, IBD Locations: Georgia, Terracon

☆ A software consultant trading stocks on the side is up 318% in 2024. He shares the stock screener he uses to find the trades he makes.
▼ + stars: | 2024-05-11 | by ( Laila Maidan | ) www.businessinsider.com time to read: +8 min

He was 13 when he first heard about trading stocks. Finally, he filters for volume with the "50-day average volume"— the average number of shares traded daily over 50 days — above 25,000 shares. He had been watching Nvidia's chart since December, and it had a consistent 200-day moving average trend upward. As of January 3rd, it held above its 50-day moving average, bouncing off resistance points around $8.83 and $8.94 with minor pullbacks. The stock had a strong 150- and 200-day average uptrend.

Persons: Leoš, Benjamin Graham's, William O'Neil, Mark Minervini, Norman Zadeh, Mikulka Organizations: Investor's, Gamestop, US, Business, Apple, Nvidia, Mitsubishi UFJ Financial, Holdings Locations: Prague, IBD

Early analyst calls on Wednesday included a downgrade to a legacy automaker and a rerating for a crypto mining stock that won big last year. "As we have parsed through our numbers, we think the road to recovery will be tougher for SEDG from the perspectives of top line, gross margins, and market share," analyst Christine Cho said. Morgan Stanley stock has slipped nearly 8% this year. The firm downgraded Ford to neutral from buy in a Tuesday note and reiterated a $12 per share price target. Ford shares have struggled this year, losing 6%.

Persons: BTIG, Wall, Joseph Spak, Spak, — Brian Evans, Barclays downgrades SolarEdge, Christine Cho, Cho, SolarEdge, JPMorgan downgrades Morgan Stanley, Morgan Stanley, Ted Pick, Kian Abouhossein, UBS downgrades Ford, Ford, Jim Farley's, Gregory Lewis, Lewis, MARA 1Y, MARA, Fred Imbert Organizations: CNBC, UBS, Ford Motor, Barclays downgrades, Barclays, SolarEdge, Enphase Energy, JPMorgan, Ford, U.S, General Motors, Crypto, Marathon, Marathon Digital, BTC Locations: U.S, Tuesday's

☆ Johnson & Johnson forecasts as much as 6% sales growth in 2024
▼ + stars: | 2023-12-05 | by ( ) www.reuters.com time to read: +2 min

Dec 5 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara. The company has narrowed its focus on its drugs and medical devices business since it hived off its consumer health unit earlier this year. Sales of blockbuster psoriasis treatment Stelara in Europe are expected to come under pressure as early as next year as a key patent on the drug expires. Sales of the drug largely come from its use as a treatment for inflammatory bowel diseases (IBD), Wolk said. J&J's 2024 revenue growth forecast excludes sales of its COVID vaccine.

Persons: Johnson, Joseph Wolk, Wolk, J, Bhanvi, Patrick Wingrove, Anil D'Silva Organizations: Johnson, Thomson Locations: Europe, United States, Bengaluru, New York

☆ Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings
▼ + stars: | 2023-10-23 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +1 min

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a "promising new therapy" for patients with Crohn's disease, Roche said in a press release. "We are eager to develop this antibody further and bring it to market and patients in the US and Japan as soon as possible." Telavant is currently owned by Pfizer and Roivant Sciences. In the Monday announcement, Roche also said it would obtain an option to collaborate with Pfizer on a new inflammatory bowel disease drug.

Persons: Roche, — Roche, Teresa Graham, Telavant Organizations: Monday, Telavant Holdings, Roche Pharmaceuticals, CNBC, Pfizer, Roivant Sciences Locations: Japan

☆ Meet Kim Posnett, the powerful Goldman Sachs dealmaker who was just named head of the investment bank's TMT unit
▼ + stars: | 2023-05-03 | by ( Reed Alexander | ) www.businessinsider.com time to read: +10 min

Kim Posnett was just named head of Goldman's all-important TMT investment banking group. Posnett, 43, has long been one of the most senior figures at Goldman's investment bank. Posnett was previously the head of Goldman's investment-banking services unit, which acts as a salesforce for the global IB division. The former co-head of Goldman's TMT franchise will become co-chairman of the unit. The former would result in the IB services group, which functions, in effect, as a sales force.

☆ Some Starbucks customers are complaining the company's new olive oil-infused coffee drink is making them run to the bathroom
▼ + stars: | 2023-04-08 | by ( Ramishah Maruf | ) edition.cnn.com time to read: +4 min

CNN —Starbucks is betting big on olive oil infused coffee, hoping customers will be enticed by the anomaly and the health benefits of extra virgin olive oil. Science behind the painOlive oil is a staple in Mediterranean culture and some drink bits of olive oil in the region daily. But the Starbucks drink has a potentially fragile combination: caffeine, which is a stimulant, and olive oil, which is a relaxant. Former CEO Howard Schultz picked up this habit himself from olive oil producer Tommaso Asaro while in Sicily, Italy. “He thought it was a little strange.” Asaro is the chairman of United Olive Oil, through which Starbucks is sourcing its olive oil.

☆ Piper Sandler did a deep analysis of banks and says these are the ones to buy on the dip
▼ + stars: | 2023-03-22 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

The repercussions from the ongoing banking crisis will take some time to play out, but Piper Sandler has names for investors to start sorting through among the wreckage. Even so, banks are dealing with tightening lending standards and rising costs that will continue to weigh on the sector. Still, some banks with strong deposit and liquidity characteristics can help investors find safe harbor, according to Piper Sandler. Here are three overweight-rated, mid-cap bank stocks that Piper Sandler highlighted: The analysts named SouthState Corporation to their list, saying they have confidence in the bank's ability to outperform peers because of its "strong low-cost, core deposit base." First Interstate BancSystem was named to the list because of its lower cost deposit base, its relatively insulated location, and its strong dividend yield.

☆ What to watch for as J&J gets ready to split into two separate companies next year
▼ + stars: | 2022-12-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +11 min

During Monday's "Morning Meeting" for members, Jim Cramer said that J & J has the "best balance sheet in America." According to projections from J & J and rival Medtronic (MDT), the robotics market captures a low 2% to 3% of global procedures. In an economic slowdown, J & J is a solid name to own that can outperform the broader market. We also like that J & J has consistently raised its dividend. We rate J & J a 1 for the Club , meaning we would buy the stock at current levels given it aligns with our strategy.

Organizations: & $

Search resuls for: "IBD"

11 mentions found